SEC Form 4 · accession 0000914190-26-000095
Envoy Medical, Inc. · COCH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brent T. Lucas
Officer — Chief Executive Officer · Director
Period of report
May 29, 2026
Accepted (ET)
Jun 4, 2026 · 4:28 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001840877
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common Stock | May 29, 2026 | A | 32,856 | $0.599 | A | 329,946 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $2.40 | holding | — | — | — | — | Oct 15, 2033 | Class A Common Stock | 879,749 | 879,749 | D |
| Stock Option (right to buy)F3 | $0.53 | holding | — | — | — | — | Feb 5, 2036 | Class A Common Stock | 200,000 | 200,000 | D |
| Warrant (right to buy)F4 | $11.50 | holding | — | — | — | — | Sep 29, 2028 | Class A Common Stock | 110,987 | 110,987 | D |
| Warrant (right to buy)F5,F6 | $0.40 | holding | — | — | — | — | — | Class A Common Stock | 37,500 | 37,500 | D |
| Warrant (right to buy)F5,F7 | $0.40 | holding | — | — | — | — | — | Class A Common Stock | 62,500 | 62,500 | D |
Explanation of responses
- F1These shares were acquired under the Envoy Medical, Inc. Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
- F2Options to purchase 659,811 shares vest on 10/15/2023, and 219,938 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months.
- F3Options to purchase 50,000 shares vest on 2/5/2027, and 150,000 shares vest pro rata on the 5th of each month thereafter for 36 consecutive months.
- F4Fully exercisable.
- F5Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants.
- F6The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device.
- F7The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device.